Who experts spoke highly of the data submitted by China for the evaluation of the new vaccine

Brussels, January 26 (reporter Zhang Penghui) – Geneva news: experts from the World Health Organization said on the 26th that China National Pharmaceutical Group and China Kexing company have submitted relevant data of two new coronal vaccines developed by them to the WHO for evaluation of the WHO emergency use list, and the who appreciates this. Katherine O’Brien, who director of immunization, vaccines and biological products, said at the press conference that at present, two kinds of Chinese vaccine products are being evaluated by who’s emergency use list, namely, the Xinguan inactivated vaccine from Sinopharm group and China Kexing company. O’Brien said the who also expects China’s new vaccine data to pass the organization’s policy assessment. Unlike the emergency use list assessment from the WHO vaccine regulatory authority, the policy assessment is conducted separately by the WHO Strategic Advisory Panel on immunization, which will make recommendations on how to use the relevant vaccines. Previously, the expert group has carried out policy evaluation on Pfizer’s and Modena’s vaccines and given suggestions on their use. According to the latest WHO documents, Sinopharm vaccine is in the process of who emergency use list evaluation. Kexing company has submitted vaccine evaluation data in mid January, and more documents are expected to be submitted by the end of this month. The final evaluation results of the two vaccines are expected to be released as early as March. In addition, Seth & middot; Berkeley, CEO of GAVI, also praised China’s efforts in the new vaccine at the press conference. The China novel coronavirus led &ldquo, the novel coronavirus pneumonia vaccine implementation plan (COVAX) &rdquo, was introduced early in the year, he said. &”China has submitted some relevant data of (new crown) vaccine to who for prequalification. This is an important step and we will continue our dialogue with China. If people are interested in acquiring these vaccines and the data shows that they can bring value to the (covax) vaccine portfolio, then we will promote cooperation with these (Chinese) companies. &”Berkeley said.

Brussels, January 26 (reporter Zhang Penghui) – Geneva news: experts from the World Health Organization said on the 26th that China National Pharmaceutical Group and China Kexing company have submitted relevant data of two new coronal vaccines developed by them to the WHO for evaluation of the WHO emergency use list, and the who appreciates this.

Katherine O’Brien, who director of immunization, vaccines and biological products, said at the press conference that at present, two kinds of Chinese vaccine products are being evaluated by who’s emergency use list, namely, the Xinguan inactivated vaccine from Sinopharm group and China Kexing company.

O’Brien said the who also expects China’s new vaccine data to pass the organization’s policy assessment. Unlike the emergency use list assessment from the WHO vaccine regulatory authority, the policy assessment is conducted separately by the WHO Strategic Advisory Panel on immunization, which will make recommendations on how to use the relevant vaccines. Previously, the expert group has carried out policy evaluation on Pfizer’s and Modena’s vaccines and given suggestions on their use.

According to the latest WHO documents, Sinopharm vaccine is in the process of who emergency use list evaluation. Kexing company has submitted vaccine evaluation data in mid January, and more documents are expected to be submitted by the end of this month. The final evaluation results of the two vaccines are expected to be released as early as March.

In addition, Seth & middot; Berkeley, CEO of GAVI, also praised China’s efforts in the new vaccine at the press conference. The China novel coronavirus led &ldquo, the novel coronavirus pneumonia vaccine implementation plan (COVAX) &rdquo, was introduced early in the year, he said. &”China has submitted some relevant data of (new crown) vaccine to who for prequalification. This is an important step and we will continue our dialogue with China. If people are interested in acquiring these vaccines and the data shows that they can bring value to the (covax) vaccine portfolio, then we will promote cooperation with these (Chinese) companies. &”Berkeley said.

留下评论

您的电子邮箱地址不会被公开。 必填项已用*标注